Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
ID: RFA-DA-25-054Type: BOTH
Overview

Topic

Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2024
Timeline
  1. 1
    Release Jan 29, 2024 12:00 AM
  2. 2
    Open Jun 25, 2024 12:00 AM
  3. 3
    Next Submission Due Jul 25, 2024 12:00 AM
  4. 4
    Close Jul 26, 2024 12:00 AM
Description

The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)". This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy for the prevention or treatment of substance use disorders (SUDs). The traditional drug discovery paradigm of single-target-based approaches has limitations in addressing the complex mechanisms and polysubstance use associated with SUDs. Polypharmacology, the study of how drug molecules interact with multiple targets, is emerging as a new paradigm for drug development in multifactorial diseases like SUDs. The use of AI/ML technologies trained in polypharmacology can enhance the discovery and development efforts by identifying the best targets, designing effective multi-target directed ligands (MTDLs), and predicting the effects of binding to multiple biological targets. The research objectives include identifying and validating disease targets, screening potential compounds, developing assays, synthesizing novel compounds, and conducting in vitro and in vivo studies. The Small Business Innovation Research (SBIR) program offers Phase I and Phase II funding opportunities to support the technical merit, feasibility, and commercial potential of the proposed research. Successful SBIR projects are expected to attract strategic partners or investors for ultimate commercialization.

Files
No associated files provided.
Similar Opportunities
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)". This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy for the prevention or treatment of substance use disorders (SUDs). The traditional drug discovery paradigm of single-target-based approaches has limitations in addressing the complex mechanisms and polysubstance use associated with SUDs. Polypharmacology, the study of how drug molecules interact with multiple targets, is emerging as a new paradigm for drug development in multifactorial diseases like SUDs. The use of AI/ML technologies trained in polypharmacology can enhance the identification of SUD pharmacotherapeutics by evaluating and predicting the effects of binding to multiple biological targets, reducing toxicity, and informing in vitro and in vivo assays. The research objectives include identifying and validating disease targets, screening potential compounds, developing assays, synthesizing novel compounds, and conducting toxicity and efficacy studies. The Small Business Innovation Research (SBIR) program offers Phase I and Phase II funding opportunities to establish technical merit, feasibility, and commercial potential. Successful SBIR projects are expected to attract strategic partners or investors for ultimate commercialization. Phase I, Fast Track, and Direct to Phase II applications are accepted in response to this solicitation. The application due date is July 25, 2024. For more information, visit the [solicitation agency website](https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-054.html).
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)". This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy for the prevention or treatment of substance use disorders (SUDs). The traditional drug discovery paradigm of single-target-based approaches has limitations in addressing the complex mechanisms and polysubstance use associated with SUDs. Polypharmacology, the study of how drug molecules interact with multiple targets, is emerging as a new paradigm for drug development in multifactorial diseases like SUDs. The use of AI/ML technologies trained in polypharmacology can enhance the discovery and development efforts for SUD pharmacotherapeutics by identifying the best targets, designing effective multi-target directed ligands (MTDLs), and predicting the effects of binding to multiple biological targets. The research objectives include identifying and validating disease targets, screening potential compounds, developing assays, synthesizing novel compounds, and conducting in vitro and in vivo studies. The Small Business Technology Transfer (STTR) program is a phased program, with Phase I focused on establishing technical merit and feasibility, and Phase II aimed at advancing the technology towards commercialization. The Fast Track option allows for the submission and review of Phase I and Phase II grant applications together, expediting the award decisions and funding for projects with high potential for commercialization.
Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the topic of "Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)". This solicitation aims to leverage AI/ML tools to identify pharmacotherapeutic development candidates with lower toxicity and higher efficacy to prevent or treat substance use disorders (SUDs). The goal is to streamline and enhance decision-making in drug discovery efforts for SUDs using AI/ML technologies. The research objectives include identifying and validating disease targets, screening potential compounds, developing assays to test candidate compounds, synthesizing novel compounds, and conducting in vitro and in vivo studies to assess efficacy and toxicity. This Small Business Technology Transfer (STTR) program is a phased program, with Phase I focused on establishing technical merit and feasibility, and Phase II aimed at advancing the technology towards commercialization. Successful projects are expected to attract strategic partners or investors for ultimate commercialization. Phase I and Fast Track applications are accepted, with Fast Track allowing Phase I and Phase II applications to be submitted and reviewed together for expedited award decisions. Milestones and deliverables must be clearly defined for Fast Track applications. The solicitation is currently open, with a release date of January 29, 2024, an open date of June 25, 2024, and a close date of July 26, 2024. More information can be found on the grants.gov website.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by Opioid and/or Stimulants use Disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus for this solicitation are pharmacotherapeutics (small molecules and biologics) and medical therapeutic and diagnostic devices, including software as a medical device. The research topics may include the development of new medications, longer-acting formulations, advanced drug delivery systems, biomarkers, imaging technologies, therapeutic devices, in vitro diagnostic assays, and digital therapeutics. The projects proposed under this solicitation may fall under Phase I, Phase II, Fast Track, or Direct to Phase II categories. The funding opportunity is open until February 15, 2025. For more information and to apply, visit the grants.gov website or the National Institutes of Health's solicitation agency URL.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulants use disorders (OUD/StUD). The current drug crisis involving opioids and stimulants has resulted in a significant number of deaths and a need for comprehensive solutions. This funding opportunity aims to support research and development activities for novel medical products that address the needs of patients suffering from OUD/StUD. The two areas of focus are pharmacotherapeutics (small molecules, biologics, natural products, etc.) and medical therapeutic and diagnostic devices (imaging technologies, therapeutic devices, diagnostic assays, etc.). The projects proposed should aim to establish technical feasibility, commercial potential, and the quality of performance of the small business awardee organization. The funding opportunity includes Phase I, Phase II, Fast Track, and Direct to Phase II applications. The deadline for applications is February 15, 2025. For more information and to apply, visit the grants.gov website or the solicitation agency URL provided.